NASDAQ:NPSP - Shire-Nps Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on delivering therapies that transform the lives of patients with rare diseases. The Company's primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved the United States Food and Drug Administration (FDA) for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The Company's second principal product, Natpara (recombinant human parathyroid hormone 1-84 [rDNA origin] injection, has been developed for hypoparathyroidism, a rare multidimensional disorder characterized by deficient or absent parathyroid hormone (PTH). The Company has collaborations or royalty agreements with Amgen, Janssen, GlaxoSmithKline and Kyowa Hakko Kirin.

Receive NPSP News and Ratings via Email

Sign-up to receive the latest news and ratings for NPSP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:NPSP
CUSIP62936P10
Phone+1-908-4505300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
OptionableNot Optionable

Shire-Nps Pharmaceuticals (NASDAQ:NPSP) Frequently Asked Questions

What is Shire-Nps Pharmaceuticals' stock symbol?

Shire-Nps Pharmaceuticals trades on the NASDAQ under the ticker symbol "NPSP."

How were Shire-Nps Pharmaceuticals' earnings last quarter?

Shire-Nps Pharmaceuticals Inc (NASDAQ:NPSP) released its earnings results on Wednesday, February, 18th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.06 by $0.08. The biopharmaceutical company earned $66.70 million during the quarter, compared to the consensus estimate of $69.30 million. View Shire-Nps Pharmaceuticals' Earnings History.

Has Shire-Nps Pharmaceuticals been receiving favorable news coverage?

News headlines about NPSP stock have trended very positive recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Shire-Nps Pharmaceuticals earned a news sentiment score of 3.7 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days.

How do I buy shares of Shire-Nps Pharmaceuticals?

Shares of NPSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Shire-Nps Pharmaceuticals' official website?

The official website for Shire-Nps Pharmaceuticals is http://www.npsp.com.

How can I contact Shire-Nps Pharmaceuticals?

Shire-Nps Pharmaceuticals' mailing address is 550 Hills Dr, BEDMINSTER, NJ 07921-1537, United States. The biopharmaceutical company can be reached via phone at +1-908-4505300.


MarketBeat Community Rating for Shire-Nps Pharmaceuticals (NASDAQ NPSP)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  272 (Vote Outperform)
Underperform Votes:  137 (Vote Underperform)
Total Votes:  409
MarketBeat's community ratings are surveys of what our community members think about Shire-Nps Pharmaceuticals and other stocks. Vote "Outperform" if you believe NPSP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NPSP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2019 by MarketBeat.com Staff

Featured Article: Outstanding Shares

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel